Coexisting of COX7A2L–ALK, LINC01210–ALK, ATP13A4–ALK and Acquired SLCO2A1–ALK in a Lung Adenocarcinoma with Rearrangements Loss During the Treatment of Crizotinib and Ceritinib: A Case Report

ALK rearrangements account for ~5% of non-small-cell lung cancer (NSCLC). Numerous rearrangement partners have been discovered. Here, we describe a 53-year-old nonsmoker with NSCLC, in whom we identified four novel rearrangements. The patient was diagnosed as adenocarcinoma in the right middle lobe...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Chengzhi, Long, Yaling, Li, Yanying, Huang, Meijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445493/
https://www.ncbi.nlm.nih.gov/pubmed/32903930
http://dx.doi.org/10.2147/OTT.S258067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445493/
https://www.ncbi.nlm.nih.gov/pubmed/32903930
http://dx.doi.org/10.2147/OTT.S258067

Ejemplares similares